Chen, Yuli
Li, Haojia http://orcid.org/0000-0001-5000-5334
Janowczyk, Andrew
Toro, Paula
Corredor, Germán http://orcid.org/0000-0003-3002-0937
Whitney, Jon
Lu, Cheng
Koyuncu, Can F.
Mokhtari, Mojgan
Buzzy, Christina
Ganesan, Shridar
Feldman, Michael D.
Fu, Pingfu http://orcid.org/0000-0002-2334-5218
Corbin, Haley http://orcid.org/0000-0002-0079-4459
Harbhajanka, Aparna
Gilmore, Hannah
Goldstein, Lori J.
Davidson, Nancy E.
Desai, Sangeeta http://orcid.org/0000-0002-3588-9888
Parmar, Vani
Madabhushi, Anant http://orcid.org/0000-0002-5741-0399
Article History
Received: 24 October 2022
Accepted: 28 April 2023
First Online: 17 May 2023
Competing interests
: A.M. is an equity holder in Elucid Bioimaging and in Inspirata Inc. In addition, he has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol Meyers-Squibb and Merck. Currently he serves on the advisory board of Aiforia Inc. He also has sponsored research agreements with Philips and Bristol Meyers-Squibb. His technology has been licensed to Elucid Bioimaging. He is also involved in a NIH U24 grant with PathCore Inc, and three different R01 grants with Inspirata Inc. S.G. has consulted for Merck, Roche, Foundation Medicine, Foghorn Therapeutics, Inspirata, Novartis and EQRX. He is also on the Scientific Advisory Board of Silagene. In addition, he has equity in Silagene and Inspirata and research funding from M2Gen. His spouse is an employee of Merck and has equity in Merck. The remaining authors declare no competing interests.